Article Information
PubMed
Published By
History
- Received October 8, 2025
- Accepted January 5, 2026
- Published online March 10, 2026.
Article Versions
- previous version (February 9, 2026 - 05:56).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright: © 2026, The Authors This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
Author Information
Funding
National Natural Science Foundation of China
82472677National Natural Science Foundation of China
82404653National Natural Science Foundation of China
U25A20103National Natural Science Foundation of China
223B2704Natural Science Foundation of Shanghai
23ZR1418900Natural Science Foundation of Chongqing
CSTB2023NSCQ-MSX0367
This work was supported by the National Natural Science Foundation of China (Grant Nos. 82472677, 82404653, U25A20103, and 223B2704), the Natural Science Foundation of Shanghai (Grant No. 23ZR1418900), and the Natural Science Foundation of Chongqing (Grant No. CSTB2023NSCQ-MSX0367).
In this issue
Jump to section
- Article
- Pan-KRAS inhibitors: broad-spectrum targeting beyond allele-specific therapies
- KRAS molecular glues: beyond conventional inhibitors toward tri-complex strategies
- Therapeutic KRAS degradation: navigating preclinical efficacy and clinical challenges for a new class of anticancer agents
- Clinical implications and future directions
- Conflict of interest statement
- Author contributions
- References
- Figures & Data
- Info & Metrics
- References
Related Articles
Cited By...
- No citing articles found.